- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01455506
PRO#0118: Decitabine Plus Mini Flu-Bu
PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Aberrant DNA methylation patterns are commonly found in malignant cells. Hypermethylation of gene promotes sequences in cancer cells resulting in transcriptional silencing of tumor suppressor genes and contributing to malignant transformation. Hypomethylating agents have been explored for the treatment of cancers such as acute myelogenous leukemia and myelodysplastic syndrome. In vitro inhibition of methylation using azanucleosides results in differentiation of transformed myeloid cells. In vivo these agents induce DNA methylation of malignant myeloid cells. The most potent DNA methylating agent currently available, decitabine, is effective in patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). About 30% of patients with MDS and an abnormal karyotype will have normalization of their karyotype after receiving the drug.
The myelodysplastic syndromes are a heterogeneous group of clonal hematologic disorders characterized by bone marrow failure and proliferation of myeloblastic leukemia cells. Patients with MDS develop cytopenias as a result of ineffective hematopoiesis. These cytopenias are believed to be a result of an increase in apoptosis resulting in an increase in futile cell cycling. In addition, the apparently mature and differentiated hematopoietic cells in patients with MDS are functionally impaired. Granulocytes have decreased myeloperoxidase activity and platelets have impaired function. Therapy for MDS includes supportive care geared mostly to transfusional support. Allogeneic transplantation has been shown to offer the possibility of long-term remission and remains the only curative option for patients with MDS. The development of reduced intensity conditioning regimens expanded the scope of allogeneic transplantation for older patients with MDS. A very large retrospective analysis by the European Blood and Marrow Transplantation Group compared the outcome of 836 patients with MDS treated with either a reduced-intensity conditioning regimen or a conventional regimen before allogeneic transplantation. The 3-year probabilities of progression-free and overall survival were similar in both groups, with a 3-year relapse rate being significantly higher in the reduced-conditioning group, offset by a significantly reduced probability of non-relapse mortality. This demonstrates the importance of the preparative regimen in preventing relapse in this setting.
Acute myeloid leukemia accounts for over 9,000 deaths yearly in the United States. The WHO classification of AML incorporates and interrelated morphology, cytogenetics, molecular genetics and immunologic markers in an attempt to construct a classification that is clinically and prognostically valid. Under this classification the requisite blast percentage in the marrow is > 20%. Hematopoietic stem cell transplantation is an established therapeutic modality in patients with AML. An alloreactive immunotherapeutic effect of donor cells has been demonstrated.
No other established therapy applied during complete remission offers as strong an anti-leukemic effect. Transplant-related morbidity and mortality, however, remain obstacles in the successful application of this treatment. More recently, reduced-intensity conditioning has been applied as a therapy for AML. Reduced-intensity conditioning, which includes potent immunosuppressive agents in addition to anti-leukemic agents, effectively permits engraftment of donor hematopoietic stem cells. Several studies have demonstrated that the morbidity and mortality are less with these regimens compared to myeloablative conditioning. While the reduced intensity of the conditioning regimen has resulted in reduced non-relapse mortality in patients with AML, some studies have suggested a concomitant increase in relapse as a consequence of lowering the intensity of the cytotoxic agents. New conditioning regimen that may increase the anti-leukemic effect while maintaining the reduced-intensity regimen toxicity profile are therefore, needed.
Decitabine is a deoxycytidine analog that rapidly enters into cells by a nucleoside-specific transport mechanism. It is then phosphorylated by deoxycytidine kinase and converted to the active triphosphate form, 5AZA-dCTP, a substrate for DNA polymerase alpha. 5AZA-dCTP is incorporated into DNA and inhibits DNA methylation as inactivating DNA methyltransferase. Decitabine is s-phase specific. A recent study randomized 170 patients with MDS to receive either decitabine or best supportive care. Patients who were treated with decitabine achieved a significantly higher overall response rate (17%) including complete responses (9%), compared with supportive care (0%). Responses were durable and were associated with transfusion independence. Patients treated with decitabine had a trend toward a longer median time to acute myelogenous leukemia (AML) progression or death compared with patients who received supportive care alone. Responses in AML have also been demonstrated with 14% complete responses and 8% partial responses in one study . Decitabine has been used in combination with cyclophosphamide and busulfan as preparative regimen in patients with AML. This regimen was associated with a high response rate, with 40% of patients with AML being still in remission more than three years after transplantation. The total dose of decitabine ranged from 400 mg/m2 to 800 mg/m2. No decitabine dose-limiting toxicity was documented. The combination of fludarabine and busulfan has been well established as a transplant regimen and is associated with a reduced regimen-related toxicity. The combination of fludarabine and busulfan is the current standard of care for AML patients undergoing allogeneic transplantation at HUMC. In this study the investigators will be using the combination of reduced-intensity fludarabine and busulfan along with decitabine 300 mg/m2.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New Jersey
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Diagnosis of acute myelogenous leukemia or myelodysplastic syndrome being considered for transplantation.
- Age 45 to 80 years or < 45 with co-morbidity including: disease not in remission
- No uncontrolled infections.
- Patients shall have a 6/6 HLA-compatible related donor or an 8/8 -HLA-compatible unrelated donor.
- KPS 70-100%
- Creatinine < 1.6 X ULN (unless age < 45 yrs)
- Serum Bilirubin < 2.5 X ULN
- Capable of giving informed consent and have signed the informed consent form.
- Cardiac EF > 50% or cardiac clearance
- Pulmonary DLCO > 50% or pulmonary clearance
Exclusion Criteria:
- Untreated CNS leukemia
- Active hepatitis or other untreated infections
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Decitabine with fludarabine and busulfan
decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation
|
Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2. Hematopoietic cells will be infused on day 0. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
To assess the effect of decitabine in combination with fludarabine and busulfan prior to allogeneic stem cell transplantation on the rate of primary graft rejection
Ramy czasowe: up to 1 year post transplantation
|
Graft failure defined by the presence of <10% donor lymphoid cells on peripheral blood analysis performed on post transplant day 84(+/- 10 days) in patients who have not relapsed will be measured.
|
up to 1 year post transplantation
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według typu histologicznego
- Nowotwory
- Choroby szpiku kostnego
- Choroby hematologiczne
- Stany przedrakowe
- Białaczka
- Zespoły mielodysplastyczne
- Białaczka, mieloidalna
- Białaczka, szpikowa, ostra
- Stan przedbiałaczkowy
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Inhibitory enzymów
- Antymetabolity, przeciwnowotworowe
- Antymetabolity
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Środki przeciwnowotworowe, alkilujące
- Środki alkilujące
- Agoniści mieloablacyjni
- Decytabina
- Fludarabina
- Busulfan
Inne numery identyfikacyjne badania
- Decitabine plus mini-FluBu
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Ostra białaczka szpikowa
-
Lundquist Institute for Biomedical Innovation at...RekrutacyjnyDługodystansowy COVID lub Post Acute Sequella COVID - PASC (U09.9)Stany Zjednoczone
-
Intermountain Health Care, Inc.Regeneron PharmaceuticalsJeszcze nie rekrutacjaPost-acute COVID-19 (PACS) lub zespół „długiego COVID-19”.Stany Zjednoczone
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalZakończonyOporna na leczenie ostra białaczka szpikowa | Zespół mielodysplastyczny RAEB-I lub RAEB-II | Oporny na leczenie CML Myeloid Blast CrisisStany Zjednoczone
Badania kliniczne na Decitabine plus Fludarabine and Busulfan
-
Gruppo Italiano Trapianto di Midollo OsseoZakończony
-
Genzyme, a Sanofi CompanyZakończonySzpiczak mnogi | Chłoniak nieziarniczyStany Zjednoczone
-
Cooperative Study Group A for HematologyZakończonyBiałaczka | Zespół mielodysplastycznyRepublika Korei
-
Hackensack Meridian HealthZakończonyZaburzenia mieloproliferacyjne | Zespół mielodysplastyczny | Ostra białaczka szpikowa | Przewlekła białaczka szpikowa | Nowotwory szpikoweStany Zjednoczone
-
Children's Oncology GroupNational Cancer Institute (NCI)Aktywny, nie rekrutującyNeuroblastoma stopnia 4S | Ganglioneuroblastoma | Neuroblastoma stopnia 2A | Neuroblastoma stopnia 2B | Neuroblastoma stopnia 3 | Neuroblastoma stopnia 4 | Neuroblastoma stopnia 1 | Neuroblastoma stopnia 2Stany Zjednoczone, Kanada, Australia, Nowa Zelandia
-
Children's Oncology GroupNational Cancer Institute (NCI)Aktywny, nie rekrutującyZlokalizowany resekcyjny nerwiak niedojrzały | Zlokalizowany nieoperacyjny neuroblastoma | Regionalny nerwiak niedojrzały | Neuroblastoma stopnia 4S | Ganglioneuroblastoma | Neuroblastoma stopnia 4Stany Zjednoczone
-
Children's Oncology GroupNational Cancer Institute (NCI)Aktywny, nie rekrutującyNerwiak zarodkowy : neuroblastoma | GanglioneuroblastomaStany Zjednoczone, Kanada, Portoryko